{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:41:19Z","timestamp":1788478879935,"version":"build-2803163510"},"reference-count":100,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.berh.2019.101474","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T08:31:03Z","timestamp":1580286663000},"page":"101474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Raynaud's phenomenon"],"prefix":"10.1016","volume":"34","author":[{"given":"Ariane L.","family":"Herrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick M.","family":"Wigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2019.101474_bib1","series-title":"De l\u2019asphyxie locale et de la gangrene sym\u00e9trique d\u00e9s extr\u00e9mites","author":"Raynaud","year":"1862"},{"key":"10.1016\/j.berh.2019.101474_bib2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4065\/78.5.603","article-title":"Skin blood flow in adult human thermoregulation: how it works, when it does not, and why","volume":"78","author":"Charkoudian","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.berh.2019.101474_bib3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/j.2040-4603.2014.tb00541.x","article-title":"Cutaneous vasodilator and vasoconstrictor mechanisms in temperature regulation","volume":"4","author":"Johnson","year":"2014","journal-title":"Comp Physiol"},{"key":"10.1016\/j.berh.2019.101474_bib4","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1113\/EP087718","article-title":"Cold-induced cutaneous vasoconstriction in humans: function, dysfunction and the distinctly counterproductive","volume":"104","author":"Alba","year":"2019","journal-title":"Exp Physiol"},{"key":"10.1016\/j.berh.2019.101474_bib5","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1042\/cs0420243","article-title":"Total and nutritional blood flow in the finger","volume":"42","author":"Coffman","year":"1972","journal-title":"Clin Sci"},{"key":"10.1016\/j.berh.2019.101474_bib6","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.17219\/acem\/75618","article-title":"Analysis of peripheral nerve and autonomic nervous system function and the stage of microangiopathy in patients with secondary Raynaud's phenomenon in the course of connective tissue diseases","volume":"27","author":"Gosk-Bierska","year":"2018","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.berh.2019.101474_bib7","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.CIR.92.6.1448","article-title":"Blockade of vasospastic attacks by alpha 2-adrenergic but not alpha 1- adrenergic antagonists in idiopathic Raynaud's disease","volume":"92","author":"Freedman","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.berh.2019.101474_bib8","doi-asserted-by":"crossref","first-page":"H243","DOI":"10.1152\/ajpheart.01305.2004","article-title":"Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries","volume":"289","author":"Bailey","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.berh.2019.101474_bib9","doi-asserted-by":"crossref","first-page":"H1278","DOI":"10.1152\/ajpregu.00631.2010","article-title":"Scraping through the ice: uncovering the role of TRPM8 in cold transduction","volume":"300","author":"McCoy","year":"2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.berh.2019.101474_bib10","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/39807","article-title":"The capsaicin receptor: a heat-activated ion channel in the pain pathway","volume":"389","author":"Caterina","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.berh.2019.101474_bib11","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/head.13596","article-title":"Raynaud's phenomenon associated with calcitonin gene-related peptide monoclonal antibody antagonists","volume":"59","author":"Evans","year":"2019","journal-title":"Headache"},{"key":"10.1016\/j.berh.2019.101474_bib12","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/art.22626","article-title":"Heritability of Raynaud's phenomenon and vascular responsiveness to cold: a study of adult female twins","volume":"57","author":"Cherkas","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.101474_bib13","first-page":"166","article-title":"Feeling of cold hands and feet is a highly heritable phenotype","volume":"15","author":"Hur","year":"2012","journal-title":"Stress Health"},{"key":"10.1016\/j.berh.2019.101474_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196279","article-title":"Association of Raynaud's phenomenon with a polymorphism in the NOS1 gene","volume":"13","author":"Munir","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.berh.2019.101474_bib15","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/art.40505","article-title":"An autoimmune basis for Raynaud's phenomenon: murine model and human disease","volume":"70","author":"Ascherman","year":"2018","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.101474_bib16","first-page":"S123","article-title":"Pilot study to determine whether transient receptor potential melastatin type 8 (TRPM8) antibodies are detected in scleroderma","volume":"33","author":"Shah","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2019.101474_bib17","first-page":"E567","article-title":"Microangiopathy in naifold videocapillaroscopy and its relations to sE- selectin, endothelin-1, and hsCRP as putative endothelium dysfunction markers among adolescents with Raynaud's phenomenon","volume":"8","author":"Gorski","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.berh.2019.101474_bib18","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1111\/jcmm.13630","article-title":"Oxidative stress in the pathogenesis of systemic scleroderma: an overview","volume":"22","author":"Vona","year":"2018","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.berh.2019.101474_bib19","article-title":"Rapid free thiol rebound is a physiological response following cold-induced vasoconstriction in healthy humans, primary Raynaud and systemic sclerosis","volume":"7","author":"Abdulle","year":"2019","journal-title":"Phys Rep"},{"key":"10.1016\/j.berh.2019.101474_bib20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.semarthrit.2017.05.004","article-title":"The role of platelets in autoimmunity, vasculopathy, and fibrosis: implications for systemic sclerosis","volume":"47","author":"Ntelis","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.101474_bib21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/cap.2019.0025","article-title":"Raynaud\u2019s phenomenon related with atomoxetine treatment in a child with autism and attention-deficit\/hyperactivity disorder","volume":"29","author":"G\u00fclle","year":"2019","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.berh.2019.101474_bib22","article-title":"Lisdexamfetamine and secondary Raynaud's phenomenon","volume":"20","author":"Gnanavel","year":"2018","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.berh.2019.101474_bib23","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","article-title":"Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database","volume":"71","author":"Meier","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 100","key":"10.1016\/j.berh.2019.101474_bib24","first-page":"S200","article-title":"Paediatric Rheumatology European Society (PRES) Juvenile Scleroderma Working Group. Raynaud's syndrome in children: systematic review and development of recommendations for assessment and monitoring","volume":"34","author":"Pain","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2019.101474_bib25","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.autrev.2010.09.013","article-title":"Undifferentiated connective tissue diseases (UCTD): simplified systemic autoimmune diseases","volume":"10","author":"Mosca","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2019.101474_bib26","first-page":"739","article-title":"Undifferentiated connective tissue disease: predictors of evolution into definite disease","volume":"35","author":"Garc\u00eda-Gonz\u00e1lez","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2019.101474_bib27","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1136\/ard.2008.106302","article-title":"The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research Group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy","volume":"68","author":"Matucci-Cerinic","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.101474_bib28","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/ard.2010.136929","article-title":"Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR scleroderma trials and research group","volume":"70","author":"Avouac","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.101474_bib29","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"Classification criteria for systemic sclerosis","volume":"65","author":"Van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.101474_bib30","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"Classification criteria for systemic sclerosis","volume":"72","author":"Van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.101474_bib31","doi-asserted-by":"crossref","first-page":"w14506","DOI":"10.4414\/smw.2017.14506","article-title":"Outcomes, rates and predictors of transition of isolated Raynaud's phenomenon: a systematic review and meta-analysis","volume":"147","author":"Ingegnoli","year":"2017","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.berh.2019.101474_bib32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archinte.158.6.595","article-title":"Outcomes in primary Raynaud's phenomenon. A meta-analysis of the frequency, rates, and predictors of transition to secondary diseases","volume":"158","author":"Spencer-Green","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.berh.2019.101474_bib33","series-title":"Raynaud's phenomenon: a guide to pathogenesis and treatment","first-page":"21","article-title":"Epidemiology of Raynaud's phenomenon","author":"Maundrell","year":"2015"},{"key":"10.1016\/j.berh.2019.101474_bib34","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1002\/art.24038","article-title":"Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis. A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis","volume":"58","author":"Koenig","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.101474_bib35","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0002-9343(82)90846-4","article-title":"A\u00a0prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report","volume":"72","author":"Harper","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.berh.2019.101474_bib36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.berh.2013.03.001","article-title":"How to perform and interpret capillaroscopy","volume":"27","author":"Cutolo","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.berh.2019.101474_bib37","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2019.101474_bib38","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/rheumatology\/kep447","article-title":"Improving outcome prediction of systemic sclerosis from isolated Raynaud's phenomenon: role of autoantibodies and nail-fold capillaroscopy","volume":"49","author":"Ingegnoli","year":"2010","journal-title":"Rheumatology"},{"issue":"Suppl 113","key":"10.1016\/j.berh.2019.101474_bib39","first-page":"S82","article-title":"From VEDOSS to established systemic sclerosis diagnosis according to ACR\/EULAR 2013 classification criteria: a French-Italian capillarascopic survey","volume":"26","author":"Vasile","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2019.101474_bib40","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/s12891-016-1206-5","article-title":"Absence of scleroderma pattern at nail fold capillaroscopy valuable in the exclusion of scleroderma in unselected patients with Raynaud's phenomenon","volume":"17","author":"Bissell","year":"2016","journal-title":"BMC Muscoskel Disord"},{"key":"10.1016\/j.berh.2019.101474_bib41","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3899\/jrheum.150900","article-title":"Quantitative alterations of capillary diameter have a predictive value for development of the capillaroscopic systemic sclerosis pattern","volume":"43","author":"Trombetta","year":"2016","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2019.101474_bib42","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00296-017-3808-0","article-title":"An international SUrvey on non-iNvaSive tecHniques to assess the mIcrocirculation in patients with RayNaud's phEnomenon (SUNSHINE survey)","volume":"37","author":"Ingegnoli","year":"2017","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.berh.2019.101474_bib43","first-page":"151","article-title":"Results from an American pilot survey among Scleroderma Clinical Trials Consortium Members on capillaroscopy use and how to best implement nailfold capillaroscopy training","volume":"37","author":"Snow","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2019.101474_bib44","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/rheumatology\/key018","article-title":"The assessment of nailfold capillaries: comparison of dermoscopy and nailfold videocapillaroscopy","volume":"57","author":"Dinsdale","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2019.101474_bib45","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1080\/14397595.2017.1404179","article-title":"An evaluation of two novel capillaroscopy techniques in suspected scleroderma-spectrum disorders: a single-centre cross-sectional study","volume":"28","author":"Parker","year":"2018","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2019.101474_bib46","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.autrev.2017.11.036","article-title":"The role of capillaroscopy and thermography in the assessment and management of Raynaud's phenomenon","volume":"17","author":"Herrick","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2019.101474_bib47","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3899\/jrheum.160791","article-title":"Evidence for a derangement of the microvascular system in patients with a very early diagnosis of systemic sclerosis","volume":"44","author":"Chora","year":"2017","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2019.101474_bib48","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.mvr.2017.04.004","article-title":"Detection of endothelial damage in patients with Raynaud's phenomenon","volume":"113","author":"Gualtierotti","year":"2017","journal-title":"Microvasc Res"},{"key":"10.1016\/j.berh.2019.101474_bib49","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1161\/CIRCULATIONAHA.115.017816","article-title":"Relation of nailfold capillaries and autoantibodies to mortality in patients with Raynaud phenomenon","volume":"133","author":"Mueller","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.berh.2019.101474_bib50","series-title":"Raynaud's phenomenon: a guide to pathogenesis and treatment","first-page":"279","article-title":"Clinical outcome measures in Raynaud's phenomenon","author":"Khanna","year":"2015"},{"key":"10.1016\/j.berh.2019.101474_bib51","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/art.40242","article-title":"Efficacy and safety of selexipag in adults with Raynaud's phenomenon secondary to systemic sclerosis. A randomized, placebo-controlled, Phase II Study","volume":"69","author":"Denton","year":"2017","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.101474_bib52","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/acr.21858","article-title":"Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials","volume":"65","author":"Gladue","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2019.101474_bib53","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.10486","article-title":"Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon","volume":"46","author":"Merkel","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.101474_bib54","first-page":"1630","article-title":"Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6","volume":"30","author":"Merkel","year":"2003","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2019.101474_bib55","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/ard.2009.107706","article-title":"The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial","volume":"69","author":"Khanna","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.101474_bib56","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/acr.23475","article-title":"Multinational qualitative research study exploring the patient experience of Raynaud's phenomenon in systemic sclerosis","volume":"70","author":"Pauling","year":"2018","journal-title":"Arthritis Care Res"},{"issue":"Suppl 71","key":"10.1016\/j.berh.2019.101474_bib57","first-page":"S103","article-title":"Use of infrared thermography as an endpoint in therapeutic trials of Raynaud's phenomenon and systemic sclerosis","volume":"30","author":"Pauling","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2019.101474_bib58","series-title":"Raynaud's phenomenon: a guide to pathogenesis and treatment","first-page":"199","article-title":"Non-invasive methods of assessing Raynaud's phenomenon","author":"Murray","year":"2015"},{"key":"10.1016\/j.berh.2019.101474_bib59","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/art.40457","article-title":"A\u00a0multicentre study of the validity and reliability of responses to hand cold challenge as measured by laser speckle contrast imaging and thermography: outcome measures for systemic sclerosis-related Raynaud's phenomenon","volume":"70","author":"Wilkinson","year":"2018","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.101474_bib60","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.autrev.2018.01.023","article-title":"Is laser speckle contrast analysis (LASCA) the new kid on the block in systemic sclerosis? A systematic literature review and pilot study to evaluate reliability of LASCA to measure peripheral blood perfusion in scleroderma patients","volume":"17","author":"Cutolo","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2019.101474_bib61","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.mvr.2010.05.012","article-title":"Excellent reproducibility of laser speckle contrast imaging to assess microvascular reactivity","volume":"80","author":"Roustit","year":"2010","journal-title":"Microvasc Res"},{"key":"10.1016\/j.berh.2019.101474_bib62","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.mvr.2011.06.012","article-title":"Comparison of infrared thermography and laser speckle contrast imaging for the dynamic assessment of digital microvascular function","volume":"83","author":"Pauling","year":"2012","journal-title":"Microvasc Res"},{"key":"10.1016\/j.berh.2019.101474_bib63","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3899\/jrheum.141437","article-title":"Use of laser speckle contrast imaging to assess digital microvascular function in primary Raynaud phenomenon and systemic sclerosis: a comparison using the Raynaud Condition Score diary","volume":"42","author":"Pauling","year":"2015","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2019.101474_bib64","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.berh.2016.04.001","article-title":"Raynaud's phenomenon","volume":"30","author":"Hughes","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.berh.2019.101474_bib65","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/rheumatology\/kev201","article-title":"Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis","volume":"54","author":"Hughes","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2019.101474_bib66","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.101474_bib67","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/1759720X17740074","article-title":"Evidence based management of Raynaud's phenomenon","volume":"9","author":"Herrick","year":"2017","journal-title":"Ther Advances Musculoskeletal Dis"},{"key":"10.1016\/j.berh.2019.101474_bib68","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40674-018-0102-6","article-title":"Pharmacotherapy options in the management of Raynaud's phenomenon","volume":"4","author":"Hinze","year":"2018","journal-title":"Curr Treat Options in Rheum"},{"key":"10.1016\/j.berh.2019.101474_bib69","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/2397198318823951","article-title":"Management of Raynaud's phenomenon in systemic sclerosis - a practical approach","volume":"4","author":"Fernandez-Codina","year":"2019","journal-title":"J\u00a0Scleroderma Relat Disord"},{"key":"10.1016\/j.berh.2019.101474_bib70","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/art.40307","article-title":"Clinical trials in Raynaud's phenomenon: a spoonful of sugar (pill) makes the medicine go down (in flames)","volume":"69","author":"Seibold","year":"2017","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.101474_bib71","series-title":"Raynaud's phenomenon: a guide to pathogenesis and treatment","first-page":"299","article-title":"Non-drug approaches to treating Raynaud's phenomenon","author":"Kwakkenbos","year":"2015"},{"key":"10.1016\/j.berh.2019.101474_bib72","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3899\/jrheum.150382","article-title":"Vasoactive therapy in systemic sclerosis: real-life therapeutic practice in more than 3000 patients","volume":"43","author":"Moinzadeh","year":"2016","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2019.101474_bib73","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/annrheumdis-2012-202836","article-title":"Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials","volume":"72","author":"Roustit","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.101474_bib74","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1111\/bcp.13314","article-title":"Fluoxetine and Raynaud's phenomeon: friend or foe","volume":"83","author":"Khouri","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.berh.2019.101474_bib75","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","article-title":"Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study","volume":"120","author":"Wigley","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2019.101474_bib76","first-page":"CD000953","article-title":"Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis","volume":"2","author":"Pope","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.berh.2019.101474_bib77","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5301\/jsrd.5000255","article-title":"Use of intravenous epoprostenol as a treatment for the digital vasculopathy associated with the scleroderma spectrum of diseases","volume":"2","author":"Law","year":"2017","journal-title":"J\u00a0Scleroderma Relat Disord"},{"key":"10.1016\/j.berh.2019.101474_bib78","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","article-title":"Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study","volume":"75","author":"Hachulla","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2019.101474_bib79","first-page":"1125","article-title":"Raynaud's phenomenon (secondary). Clinical Evidence (Online)","volume":"2014","author":"Herrick","year":"2014","journal-title":"Clin Evid"},{"issue":"4","key":"10.1016\/j.berh.2019.101474_bib80","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/1558944717715119","article-title":"Extended periarterial sympathectomy: evaluation of long-term outcomes","volume":"13","author":"Pace","year":"2018","journal-title":"Hand"},{"key":"10.1016\/j.berh.2019.101474_bib81","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bcp.12980","article-title":"Peripheral vasoconstriction induced by beta-adrenoceptor blockers: a systematic review and a network meta-analysis","volume":"82","author":"Khouri","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.berh.2019.101474_bib82","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13075-018-1605-0","article-title":"The effects of upper and lower limb exercise on the microvascular reactivity in limited cutaneous systemic sclerosis patients","volume":"20","author":"Mitropoulos","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2019.101474_bib83","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002069.pub5","article-title":"Calcium channel blockers for primary Raynaud's phenomenon","author":"Ennis","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.berh.2019.101474_bib84","first-page":"CD000467","article-title":"Calcium channel blockers for primary and secondary Raynaud's phenomenon","volume":"12","author":"Rirash","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.berh.2019.101474_bib85","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5301\/jsrd.5000232","article-title":"Digital ulcers in SSc treated with oral treprostinil: a randomized, double-blind, placebo-controlled study with open-label follow-up","volume":"2","author":"Seibold","year":"2017","journal-title":"J\u00a0Scleroderma Related Disorders"},{"key":"10.1016\/j.berh.2019.101474_bib86","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3899\/jrheum.151437","article-title":"The recurrence of digital ulcers in patients with systemic sclerosis after discontinuation of oral treprostinil","volume":"43","author":"Shah","year":"2016","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2019.101474_bib87","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1177\/1060028016660324","article-title":"Evidence for the use of epoprostenol to treat Raynaud's phenomenon with or without digital ulcers","volume":"50","author":"Cruz","year":"2016","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.berh.2019.101474_bib88","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s10067-018-4043-0","article-title":"The safety of iloprost in systemic sclerosis in a real-life experience","volume":"37","author":"Bellando-Randone","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2019.101474_bib89","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.semarthrit.2018.03.019","article-title":"Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: systematic literature review and expert consensus","volume":"48","author":"Ingegnoli","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 106","key":"10.1016\/j.berh.2019.101474_bib90","first-page":"173","article-title":"A\u00a0novel iloprost administration method with portable syringe pump for the treatment of acral ulcers and Raynaud's phenomenon in systemic sclerosis patients. A pilot study (ILOPORTA)","volume":"35","author":"Fraticelli","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2019.101474_bib91","first-page":"237","article-title":"Iloprost infusion through elastomeric pump for the outpatient treatment of severe Raynaud's phenomenon and digital ulcers - a single centre experience","volume":"43","author":"Duarte","year":"2018","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.berh.2019.101474_bib92","doi-asserted-by":"crossref","first-page":"694","DOI":"10.7326\/M18-0517","article-title":"On-demand sildenafil as a treatment for Raynaud phenomenon: a series of n-of-1 trials","volume":"169","author":"Roustit","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2019.101474_bib93","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s40261-018-0698-1","article-title":"Riociguat for the treatment of Raynaud's phenomenon: a single-dose, double-blind, randomized, placebo-controlled cross-over pilot study (DIGIT)","volume":"38","author":"Huntgeburth","year":"2018","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.berh.2019.101474_bib94","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/jdv.15180","article-title":"The clinical effects of l-arginine and asymmetric dimethylarginine: implications for treatment in secondary Raynaud's phenomenon","volume":"33","author":"Curtiss","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.berh.2019.101474_bib95","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1001\/jama.2016.5258","article-title":"Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis. DUAL-1 and DUAL-2 randomized clinical trials","volume":"315","author":"Khanna","year":"2016","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.berh.2019.101474_bib96","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/art.40123","article-title":"The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud's phenomenon: a randomized, double-blind, placebo-controlled clinical trial","volume":"69","author":"Bello","year":"2017","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2019.101474_bib97","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2340\/00015555-2665","article-title":"Efficacy of botulinum toxin B injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis","volume":"97","author":"Motegi","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.berh.2019.101474_bib98","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaad.2018.01.043","article-title":"A\u00a0systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud's phenomenon","volume":"78","author":"Curtiss","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.berh.2019.101474_bib99","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaad.2017.08.018","article-title":"Nifedipine cream versus sildenafil cream for patients with secondary Raynaud phenomenon: a randomized, double-blind, controlled pilot study","volume":"78","author":"Wortsman","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.berh.2019.101474_bib100","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ctim.2017.10.012","article-title":"Effect of topical rosemary essential oil on Raynaud phenomenon in systemic sclerosis","volume":"40","author":"von Schoen-Angerer","year":"2018","journal-title":"Compl Ther Med"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219301706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694219301706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:20:41Z","timestamp":1761499241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694219301706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1521694219301706"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2019.101474","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Raynaud's phenomenon","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2019.101474","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101474"}}